In the final stage of the Nolla Health pilot, prescriptions are fully automated by the AI, with a physician retrospectively reviewing at least 10% of the total monthly prescriptions.

Overview Debates Related claims Topics Sources

Inquiry chair Kate Lampard is considering issuing interim regulations and recommendations regarding Oxevision camera technology to prevent further avoidable patient deaths.

In 2021, NHS England raised serious patient safety concerns regarding Oxevision's usage and capability claims with the Medicines and Healthcare products Regulatory Agency.

The Medicines and Healthcare products Regulatory Agency requested clinical evidence from manufacturer Lio Health supporting claims that Oxevision reduced self-harm, but Lio Health failed to provide it.

False pulse readings produced by the Oxevision patient monitoring system were reported to the British Standards Institution in 2023.

Essex Partnership University NHS Foundation Trust spent a net total of £4.3 million on Oxevision installation, software fees, and staff training between 2020 and 2025.

Swedish researchers tested the Dermalyser AI smartphone app across 36 primary care centers from May to December 2022, evaluating 253 suspicious skin lesions in 228 patients.

Mass General Brigham radiation oncologist Dr. Raymond Mak stated that the AI facial tools aim to quantify patient physical reserve and frailty to support personalized treatment decisions.

The FAHR-FaceAge tool estimates a patient's biological age from a photo, while FAHR-FaceSurvival predicts cancer survival outcomes directly from a facial photograph.

Mass General Brigham researchers developed FAHR-Face, an artificial intelligence foundation model that powers two medical prediction tools called FAHR-FaceAge and FAHR-FaceSurvival.

The deployment of the AI triage device reduced routine dermatology follow-up appointments from 27% under standard teledermatology down to 12%.

Use of the AI medical device lowered patient biopsy rates to between 26% and 29%, compared to 43% under standard face-to-face dermatological care.

Researchers deployed the autonomous AI device in December 2024 and July 2025 at two National Health Service hospital sites in the United Kingdom, managing 8,391 patients.

An autonomous artificial intelligence device successfully managed 94% of urgent suspected skin cancer referrals during a 16-month study conducted across two U.K. hospital sites.

Researchers estimated that integrating the AI medical device resulted in a 62% increase in overall clinical capacity for dermatologists.

The AI triage device safely discharged 31% and 25% of benign skin cancer cases without clinician review at the two U.K. hospital sites.

The implementation of the AI device saved approximately 2,850 hours of clinician time, equivalent to over 8,500 face-to-face dermatology consultations.

Colon and rectal surgery expert Dr. Grace Lee stated that the FaceSurvival tool provides a standardized method to quantify clinicians' intuitive visual assessments of patient frailty.

Mass General Brigham researchers filed a patent application for the FaceSurvival artificial intelligence tool.

Penn Medicine researchers designed the Percival artificial intelligence model to advance opportunistic screening, allowing clinicians to discover early traces of unrequested health conditions like cancer or cardiovascular disease on scans ordered for other primary reasons.

India's Ministry of Health launched the Strategy for Artificial Intelligence in Healthcare for India in February 2026 to govern data, validation, deployment, and monitoring.